Objectives: Zidovudine is often administered every 12 h in HIV-infected children, but so far no pharmacokinetic data are available for the administration of this agent every 12 h. We have evaluated the plasma pharmacokinetics of zidovudine administered every 8 h versus every 12 h in HIV-1-infected children. Methods: In HIV-1-infected children who switched from zidovudine every 8 h to every 12 h, a pharmacokinetic curve was recorded both before and after the switch. Zidovudine plasma levels were measured by HPLC. Pharmacokinetic parameters were calculated by non-compartmental methods. Results: Six HIV-1-infected children [median age (range) 7.8 (2.5-13.4) years] were included. In these patients, geometric mean ratios of AUC0-24 and Cmax for zidovudine every 12 h versus every 8 h were not significantly different from 1.0. Conclusions: The plasma pharmacokinetic parameters of zidovudine taken every 8 h and every 12 h were not significantly different and therefore suggest bioequivalence of these two dose frequencies.

Additional Metadata
Keywords Paediatrics, Pharmacokinetics, Pharmacology
Persistent URL dx.doi.org/10.1093/jac/dkh490, hdl.handle.net/1765/73965
Journal Journal of Antimicrobial Chemotherapy
Bergshoeff, A.S, Fraaij, P.L.A, Verweij, C, van Rossum, A.M.C, Verweel, G, Hartwig, N.G, … Burger, D.M. (2004). Plasma levels of zidovudine twice daily compared with three times daily in six HIV-1-infected children. Journal of Antimicrobial Chemotherapy, 54(6), 1152–1154. doi:10.1093/jac/dkh490